

## DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I declare that:

My residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: **PHARMACEUTICAL ANGIOSTATIC DIPEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF** the specification of which    is attached hereto or X was filed on March 13, 1996 as Application No. 08/614,764 and was amended on    (if applicable).

I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56. I claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

## Prior Foreign Application(s)

Country	Application No.	Date of Filing	Priority Claimed Under 35 USC 119
			Yes <u>  </u> No <u>  </u>
			Yes <u>  </u> No <u>  </u>

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below:

Application No.	Filing Date

I claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, section 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Date of Filing	Status
08/538,701	October 3, 1995	<u>  </u> Patented <u>x</u> Pending <u>  </u> Abandoned
		<u>  </u> Patented <u>  </u> Pending <u>  </u> Abandoned



**POWER OF ATTORNEY:** As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

John R. Storella, Reg. No. 32,944  
 William M. Smith, Reg. No. 30,223  
 Karen B. Dow, Reg. No. 29,684  
 Jim M. Heslin, Reg. No. 29,541  
 Vern Norviel, Reg. No. 32,483

Send Correspondence to: <b>William M. Smith</b> <b>TOWNSEND and TOWNSEND and CREW</b> Steuart Street Tower One Market Plaza, 20th Floor San Francisco, CA 94105	Direct Telephone Calls to: (Name, Reg. No., telephone no.)  <b>William M. Smith</b> <b>Reg. No. 30,223</b> <b>(415) 326-2400</b>
--	---

Full Name of Inventor 1	Last Name <b>GREEN</b>	First Name <b>LAWRENCE</b>	Middle Name or Initial <b>R.</b>	
Residence & Citizenship	City <b>Tacoma</b>	State/Foreign Country <b>Washington</b>	Country of Citizenship <b>United States of America</b>	
Post Office Address	Post Office Address <b>7506 69th Avenue S.W.</b>	City <b>Tacoma</b>	State/Country <b>Washington/USA</b>	Zip Code <b>98498</b>
Full Name of Inventor 2	Last Name <b>BLASECKI</b>	First Name <b>JOHN</b>	Middle Name or Initial <b>W.</b>	
Residence & Citizenship	City <b>Woodinville</b>	State/Foreign Country <b>Washington</b>	Country of Citizenship <b>United States of America</b>	
Post Office Address	Post Office Address <b>14536 190th Avenue N.E.</b>	City <b>Woodinville</b>	State/Country <b>Washington/USA</b>	Zip Code <b>98072</b>

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of Inventor 1 	Signature of Inventor 2 
<b>Lawrence R. Green</b>	<b>John W. Blasecki</b>
Date: <b>5/6/96</b>	Date: <b>13 May 1996</b>

01359 2-002400a  
SKF

UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
ASSISTANT SECRETARY AND COMMISSIONER  
OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APRIL 28, 1998

TOWNSEND AND TOWNSEND AND CREW LLP  
SUSAN K. FARIS  
TWO EMBARCADERO CENTER, 8TH FLOOR  
SAN FRANCISCO, CALIFORNIA 94111-3834



\*100639106A\*

10542 U.S. PTO

09/506430



02/17/00

UNITED STATES PATENT AND TRADEMARK OFFICE  
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, NORTH TOWER BUILDING, SUITE 10C35, WASHINGTON, D.C. 20231.

RECORDATION DATE: 02/10/1998

REEL/FRAME: 8955/0466  
NUMBER OF PAGES: 5

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:  
CYTOVEN

DOC DATE: 01/16/1998

ASSIGNEE:  
CYTRAN, INC.  
10230 N.E. POINTS DRIVE  
SUITE 530  
KIRKLAND, WASHINGTON 98033-7869

SERIAL NUMBER: 08686004 -1-2  
PATENT NUMBER:

FILING DATE: 07/25/1996  
ISSUE DATE:

SERIAL NUMBER: 08144779 -5-2  
PATENT NUMBER:

FILING DATE: 10/28/1993  
ISSUE DATE:

SERIAL NUMBER: 08484511 -5-3  
PATENT NUMBER:

FILING DATE: 06/07/1995  
ISSUE DATE:

SERIAL NUMBER: 08415099 -8-3  
PATENT NUMBER:

FILING DATE: 03/31/1995  
ISSUE DATE:

**COPY**

SERIAL NUMBER: 08486044  
PATENT NUMBER:

-10-5

SERIAL NUMBER: 08482121  
PATENT NUMBER:

-10-6

SERIAL NUMBER: 08450904  
PATENT NUMBER:

-17

SERIAL NUMBER: 08452411  
PATENT NUMBER: 5728680

-18

SERIAL NUMBER: 08452077  
PATENT NUMBER:

-19

SERIAL NUMBER: 08452061  
PATENT NUMBER:

-20

SERIAL NUMBER: 08614764  
PATENT NUMBER:

-23-1

SERIAL NUMBER: 08337341  
PATENT NUMBER: 5538951

-10-4

FILING DATE: 06/07/1995  
ISSUE DATE: 06/16/1998

FILING DATE: 06/07/1995  
ISSUE DATE:

FILING DATE: 05/26/1995  
ISSUE DATE:

FILING DATE: 05/26/1995  
ISSUE DATE: 03/17/1998

FILING DATE: 05/26/1995  
ISSUE DATE: 06/23/1998

FILING DATE: 05/26/1995  
ISSUE DATE:

FILING DATE: 03/13/1996  
ISSUE DATE:

FILING DATE: 11/10/1994  
ISSUE DATE: 07/23/1996

SEDLEY PYNE, PARALEGAL  
ASSIGNMENT DIVISION  
OFFICE OF PUBLIC RECORDS

02-20-1998

Key Docket No. 015542-002400US

FORM PTO-1595  
(Rev. 6-93)U.S. DEPARTMENT OF COMMERCE  
Patent and Trademark Office

100639106

To the Honorable Asst. Commissioner for Patents. Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):

CYTOVEN

2. Name and address of receiving party(ies):

Name: CYTRAN, INC.

Internal Address: Suite 530

Street Address: 10230 N.E. Points Drive

City: Kirkland State: Washington ZIP: 98033-7869

Additional name(s) & address(es) attached? ☐ Yes ☒ No

3. Nature of conveyance:



Assignment



Merger



Security Agreement



Change of Name



Other:

Execution Date: January 16, 1998

4. Application number(s) or patent number(s).

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s) 08/686,004;  
08/144,779; 08/484,511; 08/415,099; 08/486,044;  
08/482,121; 08/450,904; 08/452,411; 08/452,077;  
08/452,061; 08/614,764

B. Patent No.(s) 5,538,951

Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Susan K. Faris  
TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8th Floor  
San Francisco, California 94111-3834  
(415) 576-02006. Total number of applications and patents involved 12

7. Total fee (37 CFR 3.41):..... \$ 480.00



Enclosed



Charge Fees to Deposit Account



Charge any additional fees associated with this paper or during the pendency of this application, or credit any overpayment, to deposit account

8. Deposit account number: 20-1430

02/20/1998 TTOM11 00000081 DAI:201430 5538951  
01 FC:581 480.00 CH

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Susan K. Faris

Name of Person Signing

Signature

Date

2/16/98

Atty. Reg. No. P41,739

Total number of pages including cover sheet, attachments, and document: 510. Change Correspondence Address to that of Part 5? ☒ Yes ☐ No

OMB No. 0651-0011 (exp. 4/94)

Mail documents to be recorded with required cover sheet information to:

Do not detach this portion  
Asst. Commissioner for Patents  
Box Assignments  
Washington, D.C. 20231PTO  
09/506430  
02/17/00RECEIVED  
FEB 10 1998  
RECEIPT ACCT'G DIV.

## ASSIGNMENT OF PATENTS AND PATENT APPLICATIONS

This Assignment is between CYTOVEN, a joint venture formed as a partnership under Washington law, the address of which is 10230 N.E. Points Drive, Suite 530, Kirkland, Washington, and CYTRAN, INC., a Washington corporation, the address of which is 10230 N.E. Points Drive, Suite 530, Kirkland Washington.

### RECITALS

On December 2, 1994, CYTRAN, INC., as a result of a merger of CYTOCORP, INC., a Washington Corporation, and CYTRAN, INC., acquired the interest of CYTOCORP, INC. in a joint venture named CYTOVEN. KMC, INC., a Washington corporation was the other partner in the joint venture, which was a general partnership under Washington law. Among the assets of CYTOVEN are the Patents and Patent Applications listed in SCHEDULE A.

On December 31, 1996, KMC, INC. sold its interest in the joint venture, including its share of the assets held by the joint venture, to CYTRAN, INC. for good and valuable consideration. This sale acted under Washington Corporation Law to dissolve the general partnership of CYTOVEN, (RCW § 25.04.310(3)). As indicated in a purchase agreement, the intent of the parties was to transfer all assets of CYTOVEN to CYTRAN, INC.

To wind up its affairs, CYTOVEN seeks to assign all U.S. Patents and Patent Applications in which it is the owner to CYTRAN, INC. Authority for the partnership to act in winding up its affairs after dissolution of the partnership is found in RCW § 25.04.300.

### AGREEMENT

CYTOVEN hereby assigns to CYTRAN, INC. all right, title and interest in and to U.S. Letters Patents, and Patent Applications listed in SCHEDULE A in and to any inventions disclosed therein; in and to any Letters Patent and Registrations which may hereafter be granted on the same in the United States; and to claim the priority from the Patents and Patent Applications as provided for by the laws of the United States. The right, title and interest is to be held and enjoyed by CYTRAN, INC. and CYTRAN, INC.'s successors and assigns as fully and exclusively as it would have been held and enjoyed by CYTOVEN had this assignment not been made, for the full term of any Letters

**COPY** NOT FOR RECORDATION



## SCHEDULE A

TITLE	APPLICATION SERIAL NO.	DATE FILED	PATENT NO.
METHODS OF IDENTIFYING CYTOMEDINES, COMPOSITIONS, AND USES THEREOF	08/686,004	July 25, 1996	
PHARMACEUTICAL LYSINE- CONTAINING POLYPEPTIDE COMPOSITIONS	08/144,779	October 28, 1993	
PHARMACEUTICAL LYSINE- CONTAINING POLYPEPTIDE COMPOSITIONS AND USES THEREOF	08/484,511	June 7, 1995	
PHARMACEUTICAL PREPARATION FOR THE THERAPY OF IMMUNE DEFICIENCY CONDITIONS	08/337,341	November 10, 1994	5,538,951
PHARMACEUTICAL DIPEPTIDE COMPOSITIONS AND METHODS OF USE	08/415,099	March 31, 1995	
PHARMACEUTICAL PREPARATION FOR THE THERAPY OF IMMUNE DEFICIENCY CONDITIONS	08/486,044	June 7, 1995	
PHARMACEUTICAL PREPARATION FOR THE THERAPY OF IMMUNE DEFICIENCY CONDITIONS	08/482,121	June 7, 1995	



## SCHEDULE A (cont.)

---

PHARMACEUTICAL DIPEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF: IMMUNODEPRESSANTS	08/450,904	May 26, 1995
METHODS FOR NORMALIZING NUMBERS OF LYMPHOCYTES	08/452,411	May 26, 1995
PHARMACEUTICAL DIPEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF: SYSTEMIC TOXICITY	08/452,077	May 26, 1995
METHOD FOR TREATMENT OF PURULENT INFLAMMATORY DISEASE	08/452,061	May 26, 1995
PHARMACEUTICAL ANGIOSTATIC DIPEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF	08/614,764	March 13, 1996



15542.002310  
UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
ASSISTANT SECRETARY AND COMMISSIONER  
OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

JRS

SEPTEMBER 26, 1996

PTAS

JOHN R. STORELLA  
TOWNSEND AND TOWNSEND AND CREW LLP  
TWO EMBARCADERO CENTER, 8TH FLOOR  
SAN FRANCISCO, CALIFORNIA 94111-3834



\*100225901A\*

jc526 U.S. PTO  
09/506430  
02/17/00

UNITED STATES PATENT AND TRADEMARK OFFICE  
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, NORTH TOWER BUILDING, SUITE 10C35, WASHINGTON, D.C. 20231.

RECORDATION DATE: 05/21/1996

REEL/FRAME: 8014/0777  
NUMBER OF PAGES: 3

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

GREEN, LAWRENCE R.

DOC DATE: 05/06/1996

ASSIGNOR:

BLASECKI, JOHN W.

DOC DATE: 05/13/1996

ASSIGNEE:

CYTOVEN J.V.  
10230 N.E. POINTS DRIVE SUITE 530  
KIRKLAND, WASHINGTON 98033

SERIAL NUMBER: 08614764

PATENT NUMBER:

FILING DATE: 03/13/1996  
ISSUE DATE:

SHIRLIE SIMON, EXAMINER  
ASSIGNMENT DIVISION  
OFFICE OF PUBLIC RECORDS

COPY

TOWNSEND & TOWNSEND  
L CREW  
96 OCT -4 AM 10:50  
RECEIVED

07-05-1996

Attorney Docket No. 15542-00231C

FORM PTO-1595  
(Rev. 6-93)U.S. DEPARTMENT OF COMMERCE  
Patent and Trademark Office

To the Honorable Asst. Commissioner for Patents

100225901

Documents or copy thereof.

## 1. Name of conveying party(ies):

Lawrence R. Green and John W. Blasecki

## 2. Name and address of receiving party(ies):

Name: Cytoven J.V.

Internal Address:

Street Address: 10230 N.E. Points Drive, Suite 530

City: Kirkland State: Washington ZIP: 98033

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ NoAdditional name(s) & address(es) attached? ☐ Yes ☒ No

## 3. Nature of conveyance:

- ☒ Assignment ☐ Merger  
☐ Security Agreement ☐ Change of Name  
☐ Other:

Execution Date: May 6, 1996 and May 13, 1996

## 4. Application number(s) or patent number(s).

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s) 08/614,764

B. Patent No.(s)

Additional numbers attached?

☐ Yes ☒ No

75331 U.S. PTO



07/02/96

## 5. Name and address of party to whom correspondence concerning document should be mailed:

Name: John R. Storella  
 TOWNSEND and TOWNSEND and CREW LLP  
 Two Embarcadero Center, 8th Floor  
 San Francisco, California 94111-3834  
 (415) 326-2400

6. Total number of applications and patents involved: 

7. Total fee (37 CFR 3.41):..... \$ 40.00

- ☐ Enclosed ☒ Charge Fees to Deposit Account  
☒ Charge any additional fees associated with this paper or during the pendency of this application, or credit any overpayment, to deposit account

8. Deposit account number: 20-1430

DO NOT USE THIS SPACE

## 9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

John R. Storella  
 Name of Person Signing

Signature

Date

Atty. Reg. No. 32,944

Total number of pages including cover sheet, attachments, and document:

3

10. Change Correspondence Address to that of Part 5? ☐ Yes ☒ No

OMB No. 0651-0011 (exp. 4/94)

Mail documents to be recorded with required cover sheet information to:

Do not detach this portion

Asst. Commissioner for Patents  
 Box Assignments  
 Washington, D.C. 20231

ASSIGNMENT OF PATENT APPLICATION

JOINT

WHEREAS, Lawrence R. Green of Tacoma, Washington and John W. Blasecki of Woodinville, Washington, hereinafter referred to as "Assignors," are the inventors of the invention described and set forth in the below identified application for United States Letters Patent:

Title of the Invention: **PHARMACEUTICAL ANGIOSTATIC DIPEPTIDE  
COMPOSITIONS AND METHODS OF USE THEREOF**

Date(s) of execution of Declaration: \_\_\_\_\_

Filing date: March 13, 1996 Serial No.: 08/614,764; and

WHEREAS, Cytoven J.V., a Washington joint venture company, located at 10230 N.E. Points Drive., Suite 530, Kirkland, Washington, hereinafter referred to as "Assignee," is desirous of acquiring an interest in the invention and application and in any Letters Patent and Registrations which may be granted on the same;

For good and valuable consideration, receipt of which is hereby acknowledged by Assignors, Assignors have assigned, and by these presents do assign to Assignee all right, title and interest in and to the invention and application and to all foreign counterparts (including patent, utility model and industrial designs), and in and to any Letters Patent and Registrations which may hereafter be granted on the same in the United States and all countries throughout the world, and to claim the priority from the application as provided by the Paris Convention. The right, title and interest is to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignors had this assignment not been made, for the full term of any Letters Patent and Registrations which may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof.

Assignors further agree that they will, without charge to Assignee, but at Assignee's expense, (a) cooperate with Assignee in the prosecution of U.S. Patent applications and foreign counterparts on the invention and any improvements, (b) execute, verify, acknowledge and deliver all such further papers, including patent applications and instruments of transfer and (c) perform such other acts as Assignee lawfully may request to obtain or maintain Letters Patent and Registrations for the invention and improvements

in any and all countries, and to vest title thereto in Assignee, or Assignee's successors and assigns.

IN TESTIMONY WHEREOF, Assignors have signed their names on the dates indicated.

Date: 5/6/96

Lawrence R. Green  
Lawrence R. Green

Date: 13 May 1996

John W. Blasecki  
John W. Blasecki

ASSIGN.MRG 5/94